Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality A Cohort Study

被引:250
作者
Muntner, Paul [1 ]
Whittle, Jeff [2 ]
Lynch, Amy I. [1 ]
Colantonio, Lisandro D. [3 ]
Simpson, Lara M. [4 ]
Einhorn, Paula T. [5 ]
Levitan, Emily B. [1 ]
Whelton, Paul K. [6 ]
Cushman, William C. [7 ]
Louis, Gail T. [8 ]
Davis, Barry R. [4 ]
Oparil, Suzanne [1 ]
机构
[1] Univ Alabama Birmingham, Birmingham, AL 35294 USA
[2] Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53295 USA
[3] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA
[4] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA
[5] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA
[6] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA
[7] Memphis Vet Affairs Med Ctr, Memphis, TN 38104 USA
[8] Tulane Univ, Res Off, New Orleans, LA 70118 USA
基金
美国国家卫生研究院;
关键词
LIPID-LOWERING TREATMENT; LONG-TERM; FOLLOW-UP; CARDIOVASCULAR EVENTS; EUROPEAN LACIDIPINE; REGRESSION DILUTION; RISK-FACTOR; ATHEROSCLEROSIS; ASSOCIATION; FLUCTUATION;
D O I
10.7326/M14-2803
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Variability of blood pressure (BP) across outpatient visits is frequently dismissed as random fluctuation around a patient's underlying BP. Objective: To examine the association of visit-to-visit variability (VVV) of systolic BP (SBP) and diastolic BP with cardiovascular disease (CVD) and mortality outcomes. Design: Prospective cohort study. Setting: Post hoc analysis of ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Participants: 25 814 ALLHAT participants. Measurements: The VVV of SBP was defined as the SD across SBP measurements obtained at 7 visits conducted from 6 to 28 months after ALLHAT enrollment. Participants without CVD events during the first 28 months of follow-up were followed from the 28-month visit through the end of active ALLHAT follow-up. Outcomes included fatal coronary heart disease (CHD) or nonfatal myocardial infarction, all-cause mortality, stroke, and heart failure. Results: During follow-up, 1194 fatal CHD or nonfatal MI events, 1948 deaths, 606 strokes, and 921 heart failure events occurred. After multivariable adjustment, including for mean SBP, the hazard ratio comparing participants in the highest versus lowest quintile of SD of SBP (>= 14.4 mm Hg vs. <6.5 mm Hg) was 1.30 (95% CI, 1.06 to 1.59) for fatal CHD or nonfatal MI, 1.58 (CI, 1.32 to 1.90) for all-cause mortality, 1.46 (CI, 1.06 to 2.01) for stroke, and 1.25 (CI, 0.97 to 1.61) for heart failure. Higher VVV of diastolic BP was also associated with CVD events and mortality. Limitation: Long-term outcomes were not available. Conclusion: Higher VVV of SBP is associated with an increased risk for CVD and mortality. Future studies should examine whether reducing VVV of BP lowers this risk.
引用
收藏
页码:329 / U42
页数:18
相关论文
共 33 条
  • [1] Survival in treated hypertension: follow up study after two decades
    Andersson, OK
    Almgren, T
    Persson, B
    Samuelsson, O
    Hedner, T
    Wilhelmsen, L
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1998, 317 (7152): : 167 - 171
  • [2] Long-term Blood Pressure Fluctuation and Cerebrovascular Disease in an Elderly Cohort
    Brickman, Adam M.
    Reitz, Christiane
    Luchsinger, Jose A.
    Manly, Jennifer J.
    Schupf, Nicole
    Muraskin, Jordan
    DeCarli, Charles
    Brown, Truman R.
    Mayeux, Richard
    [J]. ARCHIVES OF NEUROLOGY, 2010, 67 (05) : 564 - 569
  • [3] The predictive ability of blood pressure in elderly trial patients
    Carr, Matthew J.
    Bao, Yanchun
    Pan, Jianxin
    Cruickshank, Kennedy
    McNamee, Roseanne
    [J]. JOURNAL OF HYPERTENSION, 2012, 30 (09) : 1725 - 1733
  • [4] Clarke R, 1999, AM J EPIDEMIOL, V150, P341
  • [5] Blood Pressure Control by Drug Group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Cushman, William C.
    Ford, Charles E.
    Einhorn, Paula T.
    Wright, Jackson T., Jr.
    Preston, Richard A.
    Davis, Barry R.
    Basile, Jan N.
    Whelton, Paul K.
    Weiss, Robert J.
    Bastien, Arnaud
    Courtney, Donald L.
    Hamilton, Bruce P.
    Kirchner, Kent
    Louis, Gail T.
    Retta, Tamrat M.
    Vidt, Donald G.
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2008, 10 (10) : 751 - 760
  • [6] Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
    Davis, BR
    Cutler, JA
    Gordon, DJ
    Furberg, CD
    Wright, JT
    Cushman, WC
    Grimm, RH
    LaRosa, J
    Whelton, PK
    Perry, HM
    Alderman, MH
    Ford, CE
    Oparil, S
    Francis, C
    Proschan, M
    Pressel, S
    Black, HR
    Hawkins, CM
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) : 342 - 360
  • [7] Blood Pressure Variability and outcomes in Chronic Kidney Disease
    El Nahas, Meguid
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (12) : 4404 - 4410
  • [8] Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans
    Diaz, Keith M.
    Veerabhadrappa, Praveen
    Kashem, Mohammed A.
    Feairheller, Deborah L.
    Sturgeon, Kathleen M.
    Williamson, Sheara T.
    Crabbe, Deborah L.
    Brown, Michael D.
    [J]. HYPERTENSION RESEARCH, 2012, 35 (01) : 55 - 61
  • [9] Visit-to-Visit and Ambulatory Blood Pressure Variability as Predictors of Incident Cardiovascular Events in Patients With Hypertension
    Eguchi, Kazuo
    Hoshide, Satoshi
    Schwartz, Joseph E.
    Shimada, Kazuyuki
    Kario, Kazuomi
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2012, 25 (09) : 962 - 968
  • [10] Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967